Dr Jesús Reiné

Honorary research fellow

Jesús Reiné obtained his BSc in Biology with Hons from University of Granada, Spain in 2002. In 2004, he was awarded the prestigious CAM PhD fellowship, and subsequently he obtained his PhD in Immunology in the School of Medicine from Universidad Complutense de Madrid, Spain in 2011. Afterwards, he worked in a flow cytometry SME as a Lab Manager, where he was proactively involved in flow cytometry product development (single and combined labelled antibodies categorised as RUO, ASR and/or IVD), and in the design of innovative multiparametric flow cytometry panels, their standardisation and harmonisation with different methodological flow cytometry approaches and instruments.

From 2014 to 2022, he was part of Daniela Ferreira’s lab at LSTM  as a post-doctoral research associate and flow cytometry manager. He played a proactive and executive role in the development of innovative and challenging flow cytometry procedures successfully (conventional and spectral) for CL-2 (human challenge studies, clinical trials) and CL-3 (Tropical diseases, SARS-CoV-2) with complex multiparametric panels using non-conventional samples.

Since 2022, he joined the University of Oxford in Daniela Ferreira’s lab team within the Paediatrics Department – Medical Science Division under the umbrella of the Oxford Vaccine Group as a senior postdoc and honorary research fellow at LSTM, where is working in the development of novel vaccines using his flow cytometry expertise and associated innovative immunological methods.


  • Development of innovative immunological methods and biomarkers
  • Mucosal (nasal and lung) immune responses to respiratory pathogens
  • Host and pathogen interactions during respiratory bacterial and viral co-infections


Since 2014, I am teaching flow cytometry methods and biosafety procedures in CL-2 and CL-3 scenario to master students, research assistants and researchers. Due to my flow cytometry expertise, I am also part of the invited lecturers to the Immunology course of the Masters in Tropical Disease Biology at LSTM (TROP738,739) and the Immunology Master at the Universidad Complutense de Madrid. At Oxford, I am also the coordinator and main responsible of the SuperUsers (trainers of flow cytometry) composed by 11 instruments and 9 trainers at the IDRM, the standardisation of the trainings and their coordination. 

Selected publications

  • Detection of SARS-CoV-2 infection by saliva and nasopharyngeal sampling in frontline healthcare workers: An observational cohort study. PLoS One. 2023 Jan 27;18(1):e0280908. doi: 10.1371/journal.pone.0280908. eCollection 2023.

    Human Infection Challenge with Serotype 3 Pneumococcus..Am J Respir Crit Care Med. 2022 Dec 1;206(11):1379-1392. doi: 10.1164/rccm.202112-2700OC.PMID: 35802840

    Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2). BMJ Open. 2022 Jul 7;12(7):e062109. doi: 10.1136/bmjopen-2022-062109.

    Targeted Transcriptomic Screen of Pneumococcal Genes Expressed during Murine and Human Infection. R.Infect Immun. 2022 Jul 21;90(7):e0017522. doi: 10.1128/iai.00175-22. Epub 2022 Jun 8.

    Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization. J Clin Invest. 2022 Jun 1;132(11):e161565. doi: 10.1172/JCI161565.

    Influence of sex, season and environmental air quality on experimental human pneumococcal carriage acquisition: a retrospective cohort analysis. ERJ Open Res. 2022 Apr 11;8(2):00586-2021. doi: 10.1183/23120541.00586-2021. eCollection 2022 Apr.

    Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2. J Clin Invest. 2022 Apr 1;132(7):e157124. doi: 10.1172/JCI157124.